▲ | Manuel_D 6 days ago | |||||||||||||||||||||||||
No, I don't think patients want to have brittle bones that are much more likely to break. I don't think patients wanted to never experience an orgasm. These are not desired outcomes. These are unintended negative side effects of preventing natural puberty. Again, the claim is that puberty blockers are reversible. A natal male patient that is unsure of their identity and takes puberty blockers for some time then ceases treatment will on average be shorter than if he had never taken blockers. They are not reversible. The effects of puberty blockers are permanent. The Cass Review found that rates into regretted transition were very limited because they didn't follow up with patients for long periods of time. In particular, the youth gender clinics in the UK didn't follow up with any patients after the age of 18. So when they say that they measured an incredibly low rate of regret, understand that this is a low percentage of patients that reported regret by the age of 18. Someone who started to regret it at 19 or in their 20s is not counted. What the Cass Review found was that bodies like WPATH and AAP were claiming low rates of regret when the evidence base for that claim was extremely weak. Evidence based medicine doesn't mean we just adopt any anything goes stance until it's been proven that treatment is harmful. Evidence based medicine means we don't give treatment until we have evidence that treat confers good outcomes - at least not outside of a research setting. | ||||||||||||||||||||||||||
▲ | notahacker 6 days ago | parent [-] | |||||||||||||||||||||||||
I don't think patients who want to be addressed as a women particularly wish to end up 6'4" tall with broad shoulders, but those are unintended side effects of unwanted puberty for a significant number of people currently requesting blockers. So being smaller is literally an intended effect of choosing blockers. And the relatively small proportion of natal male patients that cease treatment go through puberty, hence the primary effect is not irreversible. Being statistically slightly smaller in stature wouldn't typically be classed as a harmful side effect of any other course of treatment, particularly where the purpose of the treatment was to ensure those choosing to continue successfully avoid more drastic and completely irreversible changes in stature before making a decision on hormones which actually are extremely difficult to reverse. Since we're insisting that WPATH and the AAP's evidence base is a bit thin, I'm sure I'm going to be wowed by the list of citations you produce for puberty blockers causing significant harm in the form of "brittle bones that are much likely to break"... The Cass Review found that a children's clinic didn't conduct followup exercises with adults and didn't regard other followup studies involving adult cohorts as conclusive. I haven't disputed that, or that medicine is typically more cautious than other sciences. What I am disputing is that the Cass Report concluded that puberty blockers were dangerous and irreversible when prescribed to people with gender dysphoria. I mean, if she actually believed that had been established, she wouldn't be recommending trials, right... | ||||||||||||||||||||||||||
|